NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

So then is the 13% five year survival rate for GBM patients in the treatment arm a joke to you, and your friends?
Especially when around 60% of the GBM patients in the DCVax-L trial were unmethylated.

Median survival rate of eight months; 5-year survival rate of 6.8%
https://braintumor.org/brain-tumors/about-brain-tumors/brain-tumor-types/astrocytoma/#glioblastoma

Anybody with a clue in this space knows that is a JOKE. - exwannabe

And how about the 13.2 mOS of the recurrent GBM patients in the DCVax trial? Is that a joke to you and your buddies too?

Most GBM recurs in 6 to 9 months and the median OS since recurrence is 3 to 9 months. Despite advancements in clinical trials, there is no uniform standard of care (SOC) for recurrent GBM.
https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.e14057#:~:text=Abstract-,e14057,(SOC)%20for%20recurrent%20GBM.

Those OS stats are facts that the regulators are not going to ignore.